Clinical Trials | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Athena is also exploring the use of this technology for expanded carrier screening
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
Subscribe To Our Newsletter & Stay Updated
